Novartis AG
NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
$160.79−0.31 (-0.19%)
Close on Oct 30, 2026Market cap $306.81BP/E 22.5Yield –
Novartis Net Sales in the U.S.: $21,154M in FY2025, up 12.0% from a year earlier.
Latest, FY2025
21,154
Period ended Dec 31, 2025
Change on a year earlier
+12.0%
18,885 in FY2024
History
4 years
Since FY2022
Sources
4
Documents cited below
Where the FY2025 figure comes from
“|| Top 20 brands total | 21 154 | 11 | 23 359 | 12 | 11 | 44 513 | 12 | 11”
Source: Novartis Form 6-K (0001114448-26-000007) ↗
Reported in Form 6-K & Form 20-F (Top 20 Brands US / Rest of World).
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Net Sales in the U.S. ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 21,154 | +12.0% | Novartis Form 6-K (0001114448-26-000007) ↗ |
| FY2024 | Dec 31, 2024 | 18,885 | +26.3% | Novartis Form 6-K (0001370368-25-000007) ↗ |
| FY2023 | Dec 31, 2023 | 14,952 | +17.2% | Novartis Form 6-K (0001370368-24-000007) ↗ |
| FY2022 | Dec 31, 2022 | 12,753 | – | Novartis Form 6-K (0001370368-23-000008) ↗ |
Breakdown
What makes up net Sales in the U.S.
Cite this data
StockData. (2026). Novartis Net Sales in the U.S. ($M), annual FY2022–FY2025 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/portfolio-top20-us-sales
See every metric in the Novartis KPI table. Data updated Nov 2, 2026.